Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanofi trivalent seasonal influenza vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Sanofi's trivalent seasonal influenza vaccine is an inactivated split-virus vaccine designed to protect against three strains of the influenza virus. For the 2025–2026 U.S. flu season, the FDA-recommended composition for egg-based vaccines includes an A/Victoria/4897/2022 (H1N1)pdm09-like virus, an A/Croatia/10136RV/2023 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus. The cell- or recombinant-based formulation uses slightly different H1N1 and H3N2 strains but retains the same B strain[2]. The mechanism of action involves stimulating the immune system to produce antibodies against these viral antigens, thereby providing protection from infection and its complications[6][9]. The primary indication is prevention of seasonal influenza in eligible populations as recommended by public health authorities.
- Brand names
- Fluzone
- Other names
- Sanofi trivalent inactivated influenza vaccineSanofi trivalent flu vaccineFluzone Trivalent (historical)Sanofi Pasteur trivalent influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Sanofi trivalent seasonal influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanofi trivalent seasonal influenza vaccine.